Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626548 · ClinicalTrials.gov registry record · Phase 3
A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,577
- Enrollment target
NCT00626548 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2,577 participants.
The verdict
NCT00626548, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,577 participants
- Enrollment target
Study Summary
Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC). This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve progression-free survival and overall survival against a background of existing prostate cancer treatments. ZD4054 (Zibotentan) is a new type of agent, which is thought to slow tumour growth and spread by blocking Endothelin receptor activity. This trial will look at the effects of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC) patients who have had rising PSA after surgical or medical castration but have no evidence of metastases. All patients participating in this clinical trial will receive existing prostate cancer treatments in addition to trial therapy. Half the patients will receive ZD4054 (Zibotentan) , and half the patients will receive placebo in addition to standard prostate cancer therapy. By participating in this trial there is a 50% chance that patients will receive an agent that may slow the progression of the tumour. No patients will be deprived of standard prostate cancer therapy.
Interventions
- DRUG ZD4054
- DRUG Palcebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,577 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626548
The ClinicalTrials.gov registry entry for NCT00626548 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,577 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ZD4054 is the first listed.
NCT00626548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626548 about?
NCT00626548 is a clinical study titled "A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer". Enthuse M0 is a large phase III clinical trial studying the efficacy of ZD4054 (Zibotentan) in hormone resistant prostate cancer (HRPC). This clinical trial will test if the Endothelin A Receptor Antagonist ZD4054 (Zibotentan) can improve progression-free survival and overall survival against a bac...
What is the current status of trial NCT00626548?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,577 participants. The study started on 2008-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00626548?
The interventions under investigation include: ZD4054 (DRUG), Palcebo (DRUG).
Who is sponsoring clinical trial NCT00626548?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.